OTX-14-002: Device Exposure Registry
Withdrawn
- Conditions
- Endophthalmitis
- Registration Number
- NCT02309736
- Lead Sponsor
- Ocular Therapeutix, Inc.
- Brief Summary
The objective of the study is to collect post-approval data relative to the incidence of endophthalmitis for cataract surgery patients treated with the FDA-approved ReSure Sealant when used by a broad group of physicians under commercial use conditions
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of endophthalmitis Day 30
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the incidence rate of endophthalmitis after ReSure Sealant use in clear corneal cataract surgery according to NCT02309736?
How does ReSure Sealant compare to traditional suturing techniques in preventing postoperative endophthalmitis?
Are there specific ocular biomarkers that correlate with increased risk of endophthalmitis following ReSure Sealant application?
What are the long-term safety outcomes and adverse event profiles associated with ReSure Sealant in commercial use settings?
What alternative corneal incision sealing technologies are being evaluated for endophthalmitis prevention in cataract surgery?